Resources Repository
-
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
Tutorial/PrimerPublication, Teaching Resource 2015White Paper: Retrospective Benefit-Cost Analysis
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote …
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote understanding of the impacts after a policy is implemented. Serving as a brief primer, the authors propose that analysis can be useful for identifying needed reforms as well as in improving the conduct of future prospective analyses. The major challenges relate to estimating what would have occurred in the absence of the policy and separating the effects of the policy…
Priority Setting/Ethics | Benefit-Cost Analysis | Social Determinants | Environmental Health | Policy/Regulation | Culture/Society | Economics/Finance | Government/Law | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Policy Translation -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2015Salt Reduction Policy in South Africa: Extended Cost-Effectiveness Analysis
This paper is an extended cost-effectiveness analysis to model the potential health and economic impacts of …
This paper is an extended cost-effectiveness analysis to model the potential health and economic impacts of a salt reduction policy in South Africa. The authors used surveys and epidemiologic studies to estimate reductions in CVD resulting from lower salt intake. They calculated the average out-of-pocket (OOP) cost of CVD care and estimated the reduction in OOP expenditures and government subsidies due to the policy. They also estimated the costs of policy implementation and financial risk protection (FRP) benefits. The…
Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine | Sub-Saharan Africa -
Tutorial/PrimerPublication, Teaching Resource 2015Educational Review of the Statistical Issues in Utility Data for CEA
The aim of cost-utility analysis is to support decision making in healthcare by providing a …
The aim of cost-utility analysis is to support decision making in healthcare by providing a standardized mechanism for comparing resource use and health outcomes across programmes of work. The focus of this review is the denominator of the cost-utility analysis, specifically the methodology and statistical challenges associated with calculating QALYs from patient-level data collected as part of a trial. The authors provide a brief description of the most common questionnaire used to calculate patient level…
Preferences/Values | Health Outcomes | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2015Clinical Role and Cost-Effectiveness of Long-Acting ART
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with …
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with poor daily ART adherence. In this study the clinical role and cost-effectiveness of 3 long-acting ART strategies (LA-ART for patients with multiple ART failures; second-line LA-ART for those failing first-line therapy; and first-line LA-ART for ART-naive patients) are compared to daily oral ART using a microsimulation model. The findings of this study showed that LA-ART could improve survival of…
Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Evidence Synthesis | Costing Methods | Health Outcomes | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Europe -
ReviewPublication 2015Agent-Based Models and Microsimulation
This article reviews the principles and applications of agent-based models (ABMs). ABMs are computational models …
This article reviews the principles and applications of agent-based models (ABMs). ABMs are computational models used to simulate the actions and interactions of “agents” within a system. Usually, each agent has a set of rules for how he or she responds to the environment and to other agents. These models are used to gain insight into the emergent behavior of complex systems with many agents, in which the emergent behavior depends upon the micro-level behavior…
Microsimulation | Mathematical Models | State-Transition | Dynamic Simulation | Energy/Engineering | Health/Medicine | Military/Defense | Science/Technology -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Health Systems | Policy/Regulation | Clinical Care | Economics/Finance | Health/Medicine | Asia & Pacific